Updates in the Treatment of HR+/HER2- Breast Cancer - Episode 5

Clinical Perspectives: Use of CDK4/6i After CDK4/6i

Panelists discuss potential treatment options for patients following progression on CDK4/6 inhibitors (i) in HR+/HER2– metastatic breast cancer.

Video content above is prompted by the following:

Dr. Bardia to Dr. Chan: Can you please review the potential options for after CK4/6i progression: